Patrick F. Kelly, Concord, MA (US); Susan Ashwell, Carlisle, MA (US); Blythe Thomson, Cincinnati, OH (US); Alan Collis, Lexington, MA (US); Jeff Davis, Hingham, MA (US); Duncan Walker, Boulder, CO (US); and Wei Lu, Newton, MA (US)
Assigned to FORMA Therapeutics, Inc., Watertown, MA (US)
Filed by FORMA Therapeutics, Inc., Watertown, MA (US)
Filed on Mar. 21, 2022, as Appl. No. 17/700,027.
Application 17/700,027 is a continuation of application No. 16/893,147, filed on Jun. 4, 2020, granted, now 11,311,527.
Application 16/893,147 is a continuation in part of application No. PCT/US2020/033212, filed on May 15, 2020.
Application PCT/US2020/033212 is a continuation of application No. 16/526,593, filed on Jul. 30, 2019, granted, now 11,013,734, issued on May 25, 2021.
Application 16/893,147 is a continuation in part of application No. 16/526,593, filed on Jul. 30, 2019, granted, now 11,013,734, issued on May 25, 2021.
Application PCT/US2020/033212 is a continuation in part of application No. 16/431,588, filed on Jun. 4, 2019, granted, now 11,013,733, issued on May 25, 2021.
Application 16/893,147 is a continuation in part of application No. 16/431,588, filed on Jun. 4, 2019, granted, now 11,013,733, issued on May 25, 2021.
Application 16/526,593 is a continuation in part of application No. 16/431,588, filed on Jun. 4, 2019, granted, now 11,013,733, issued on May 25, 2021.
Application 16/431,588 is a continuation in part of application No. 16/414,505, filed on May 16, 2019, granted, now 11,576,906.
Application 16/414,505 is a continuation in part of application No. PCT/US2019/032747, filed on May 16, 2019.
Application 16/431,588 is a continuation in part of application No. PCT/US2019/032742, filed on May 16, 2019.
Application PCT/US2019/032742 is a continuation in part of application No. PCT/US2019/032747, filed on May 16, 2019.
Application PCT/US2019/032747 is a continuation in part of application No. 16/414,505, filed on May 16, 2019, granted, now 11,576,906.
Application PCT/US2020/033212 is a continuation in part of application No. PCT/US2019/032747, filed on May 16, 2019.
Application PCT/US2019/032747 is a continuation in part of application No. 16/414,505, filed on May 16, 2019, granted, now 11,576,906.
Application 16/431,588 is a continuation in part of application No. 16/414,716, filed on May 16, 2019, granted, now 10,532,047, issued on Jan. 14, 2020.
Claims priority of provisional application 63/023,813, filed on May 12, 2020.
Claims priority of provisional application 62/812,367, filed on Mar. 1, 2019.
Claims priority of provisional application 62/798,677, filed on Jan. 30, 2019.
Claims priority of provisional application 62/798,690, filed on Jan. 30, 2019.
Claims priority of provisional application 62/798,687, filed on Jan. 30, 2019.
Claims priority of provisional application 62/798,681, filed on Jan. 30, 2019.
Claims priority of provisional application 62/798,684, filed on Jan. 30, 2019.
Claims priority of provisional application 62/773,562, filed on Nov. 30, 2018.
Claims priority of provisional application 62/712,160, filed on Jul. 30, 2018.
Claims priority of provisional application 62/701,487, filed on Jul. 20, 2018.
Claims priority of provisional application 62/692,591, filed on Jun. 29, 2018.
Claims priority of provisional application 62/692,605, filed on Jun. 29, 2018.
Claims priority of provisional application 62/692,598, filed on Jun. 29, 2018.
Claims priority of provisional application 62/692,604, filed on Jun. 29, 2018.
Claims priority of provisional application 62/692,601, filed on Jun. 29, 2018.
Claims priority of provisional application 62/680,560, filed on Jun. 4, 2018.
Claims priority of provisional application 62/680,566, filed on Jun. 4, 2018.
Claims priority of provisional application 62/680,562, filed on Jun. 4, 2018.
Claims priority of provisional application 62/680,571, filed on Jun. 4, 2018.
Claims priority of provisional application 62/672,462, filed on May 16, 2018.
Claims priority of provisional application 62/672,461, filed on May 16, 2018.
Prior Publication US 2023/0066088 A1, Mar. 2, 2023
1. A method of treating a patient diagnosed with a solid tumor characterized by an IDH1 mutation, the method comprising orally administering to the patient in need thereof a pharmaceutical composition comprising a total of 150 mg of olutasidenib twice per day (BID).